LustGarden Foundation for Pancreatic Cancer Research

Pancreatic Cancer Research

As the largest private funder of pancreatic cancer research, we are relentlessly focused on improving patient outcomes and we are making progress every day. Thanks to separate funding to support administrative expenses, 100 percent of every donation goes directly to research.

Navigating Pancreatic Cancer

We are here to empower you to ask bold questions, seek out the best treatment options, and face the unique challenges of pancreatic cancer head-on. We want to give you the resources and information you need to make informed decisions that are best for you.

Patient Checklist

Checklist

August 1, 2018 ladmin

As overwhelming as a pancreatic cancer diagnosis is, it is important to act quickly and put a treatment plan into place. Treatment should ideally begin within one month after you receive your diagnosis. Understand your disease. Thoroughly understand what stage of pancreatic cancer you have and inquire about having your blood and tumor genetically sequenced. […]

Research

Clinical Trials Finder

July 30, 2018 ladmin

If you have been diagnosed with pancreatic cancer, a clinical trial may be your best treatment option. Many clinical trials are underway for patients in all stages of the disease and may involve new combinations of currently available drugs or new drugs that have worked in other cancers. No matter where you are in your journey, we encourage you to learn more about clinical trials.

Lets Win! Pancreatic Cancer

Let’s Win! Pancreatic Cancer

July 20, 2018 ladmin

LET’S WIN! Pancreatic Cancer A Dynamic Way to Share Information Recognizing that there is an urgent need for patients to communicate amongst themselves and with the medical community about potentially life-changing treatments and clinical trials, we are proud to be affiliated with Let’s Win. Let’s Win is an interactive online community where patients and families […]

Pancreatic Cancer Connections

July 7, 2018 ladmin

Pancreatic Cancer Connections is online social community that provides a safe space for pancreatic cancer patients and their loved ones to share their experiences, get valuable coping resources, and support one another. Patients interact with others who are facing a pancreatic cancer and can post questions to the board or message other members privately. This community forum is a valuable resource for patients, caregivers, and their loved ones to refer to at various stages of their treatment and recovery.

Patients and loved ones can sign up for Pancreatic Cancer Connections at no cost and will be welcomed into an engaging and supportive community to discuss topics including treatment options, nutrition, and coping with the disease. Pancreatic Cancer Connections is hosted by Inspire, a leading healthcare social network that connects more than 1,000,000 patients and caregivers.

Lustgarten News

View All Articles

Changing
Lives Through Early Detection

No one is ever fully prepared to face a pancreatic cancer diagnosis, but in Scott Nelson’s case, the prognosis was devastating; the size and location of his tumor made it inoperable. Feelings of shock, disbelief and anger flooded this loving father’s mind as he thought about his three daughters—and their eventual life without him. But another feeling arose within Scott: determination. He sought a second opinion and joined a clinical trial using a combination of chemotherapy, immunotherapy and radiation. The combined treatment worked to shrink Scott’s tumor so he could then undergo life-saving surgery. Scott has now been disease-free for 15 years, grateful for the countless memories and milestones he’s experienced with his family and committed to advocating for other patients and supporting early detection research.

Learn More

Focusing on Pancreatic Cancer Prevention

A Better Future For Families Impacted by Pancreatic Cancer

The GENERATE (GENetic Education, Risk Assessment, and TEsting) Study is designed for people who have a close relative with pancreatic cancer that may have been caused by an inherited mutation in a gene. The goal of this study is to improve genetic testing and cancer prevention in family members of pancreatic cancer patients. If a family member does have an inherited risk, there may be options for preventing cancer or detecting it early at a curable stage via regular cancer screenings.

To be eligible for the GENERATE Study, participants must:

    • Have a first-degree relative* who has (or had) pancreatic cancer or a second-degree relative* who has (or had) pancreatic cancer and has a known genetic mutation
    • Be able to provide the genetic test report of the family member with a genetic mutation (if genetic testing has been done in the family)
    • Not have had pancreatic cancer
    • Not have had genetic testing or counseling for cancer risk before
    • Have a healthcare provider and be willing to share genetic test results with that provider and the GENERATE Study team
    • Be willing to complete a series of questionnaires for up to 15 months
    • Be age 18 or older
    • Have a United States mailing address
    • Have Internet access

Learn More

Our Response to COVID-19

How Lustgarten is Responding to COVID-19

A letter from the CEO

Hi and thank you for checking in with the Lustgarten Foundation to learn more about our response to the novel coronavirus, or COVID-19.

Seemingly overnight, COVID-19 has dramatically changed the world in which we live. I sincerely hope you and your loved ones are well.

We at the Lustgarten Foundation are doing our best to follow the CDC guidelines, practice social distancing and to help flatten the curve. As of Tuesday, March 17, all staff are working remotely, but we are staying in touch with one another and continue to be here for you. Though images from major cities and small towns across the country almost make it feel that life has stopped, we know the fight against pancreatic cancer cannot wait.

For now, we have postponed or cancelled all events through the end of May—if you were already registered for one of these events, you should have received an email with everything you need to know. If you missed the email or are just now considering registering for an event, we’ve posted all the details below. Of course, if you have questions about pancreatic cancer, fundraising, walks or anything else, please get in touch. Call us tollfree at 866-789-1000 or send an email to contactus@lustgarten.org. We check the messages daily and one of us will get back to you as soon as possible.

To keep up with the latest pancreatic cancer research information and Lustgarten Foundation activities, follow us on Facebook, Instagram, LinkedIn and Twitter.

We know this is a difficult and uncertain time, and we also know we will get through this together. Please follow the recommendations of your healthcare provider and practice social distancing as much as possible (but remember, Skype and FaceTime are great options to keep you connected with friends and family) and stay healthy and safe.

 

 

Kerri Kaplan,
President and CEO

Learn More

Pancreatic Cancer News

View All Articles

Study suggests new potential strategy to fight against pancreatic cancer

6. 7. 20 ladmin

A University of Michigan-led study is shedding new light on the way pancreatic cancer cells turn nearby connective tissue cells into co-conspirators in their deadly growth. The findings, which appear in Nature Metabolism, also suggest a new potential strategy against pancreatic cancer by identifying critical components of metabolic cross talk between cells that might be attacked […]

Ipsen scores FDA fast-track for Onivyde in first-line pancreatic cancer

19. 6. 20 ladmin

The FDA designation will review the use of Onivyde (liposomal irinotecan) in combination with 5- fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX), also known as Nalirifox, in patients with previously untreated, unresectable, locally advanced and metastatic pancreatic ductal adenocarcinoma (PDAC). The fast-track programme aids the development and also expedites the review of drugs that are designed to treat serious […]

Researchers find a new therapeutic target in pancreatic cancer

18. 6. 20 ladmin

The development of pancreatic cancer is driven by co-existing mutations in an oncogene involved in controlling cell growth, called KRAS, and in a tumor suppressor gene, called p53. But how these mutations cooperate to promote cancer is unknown. A new study co-led by Steven Leach, MD, Director of Dartmouth’s and Dartmouth-Hitchcock’s Norris Cotton Cancer Center […]

Research points to potential new treatment for pancreatic cancer

8. 6. 20 ladmin

As the next step in finding a potential targeted treatment for pancreatic cancer, researchers at the University of Cincinnati are publishing a new study revealing how a combination therapy may improve outcomes for patients with this disease. The study, led by graduate research assistant Kombo N’Guessan, Ph.D., and Xiaoyang Qi, Ph.D., professor in the Division […]

Revealed: How cancer develops resistance to treatment

5. 6. 20 ladmin

Cancer cells can turn on error-prone DNA copy pathways to adapt to cancer treatment, a breakthrough study published in the journal Science has revealed. Bacteria use the same process, termed stress-induced mutagenesis, to develop antibiotic resistance. The cells of the human body are constantly dividing, and each time need to copy a three billion-letter DNA […]

Identifying Patients With Pancreatic Cancer Likely to Respond

2. 6. 20 ladmin

The presence of either germline or somatic mutations that encode proteins involved in a form of DNA repair known as homologous recombination (HR) identifies patients with advanced pancreatic cancer who are going to respond best to first-line (1L) platinum therapy, new research shows. From 5% to 9% of patients with pancreatic cancer harbor germline or somatic mutations […]

Chemotherapy prior to surgery may help outcomes for patients with pancreatic cancer

20. 5. 20 ladmin

A clinical trial led by researchers from the University of Cincinnati has found that one-third of patients receiving chemotherapy before surgery for pancreatic cancer had very encouraging results at the time of the procedure. The results of this National Cancer Institute’s SWOG Cancer Research Network trial will be presented as part of the ASCO20 Virtual […]

Why pancreatic ductal adenocarcinoma is so lethal

19. 5. 20 ladmin

Pancreatic ductal adenocarcinoma (PDA) is a deadly cancer, killing patients within a year. CSHL Professor Christopher Vakoc and his former postdoc Timothy Somerville discovered how pancreatic cells lose their identity, acquire a deadly new identity, and recruit nearby cells to help them grow, promote inflammation, and invade nearby tissues. This understanding could lead to new therapies […]

Another Step Towards Earlier Detection of Pancreatic Cancer

23. 4. 20 ladmin

— Risk-prediction model uses biomarkers added to clinical and genetic risk factors A risk-prediction model combining genetic and clinical factors with circulating biomarkers can identify people at notably higher than normal risk of pancreatic cancer who could benefit from screening and early detection, a U.S. nested case-control analysis suggested. The study’s final integration of three […]

Join Us

Get Involved Today

Get inspired and connect with patients, survivors and loved ones who are all on the same journey.

Back to Top